Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navelbine/Epirubicin vs Navelbine/Mitozantrone vs Cyclophosphamide/Adriamycin in Early Breast Cancer
NCT00004237Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 1998
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine, epirubicin and mitoxantrone in breast cancer (3 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Objective Tumor Response at 18 weeks, Clinical Complete Remission at 18 weeks and 2 more. Started Oct 1998; status: completed.
02
Drugs
vinorelbineepirubicinmitoxantrone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004237.